A Study to Evaluate the Use of Memantine In Combination With Anti-HIV Drugs to Treat AIDS Dementia Complex (ADC)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00000867 |
Recruitment Status
:
Completed
First Posted
: August 31, 2001
Last Update Posted
: June 10, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of this study is to determine the safety and effectiveness of memantine, an experimental drug, in improving AIDS dementia complex (ADC).
The symptoms of ADC can be improved with zidovudine (ZDV). However, ZDV therapy has been associated with significant toxicities, and the effectiveness of ZDV seems to decrease during the second and third years of therapy. The effectiveness of other antiretroviral drugs as treatment for ADC is not known, so it is important to explore alternative therapies.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
AIDS Dementia Complex HIV Infections | Drug: Memantine | Phase 2 |
The signs and symptoms of the AIDS Dementia Complex can be alleviated by zidovudine (ZDV). However, ZDV therapy has been associated with significant toxicities, particularly bone marrow suppression. The efficacy of ZDV appears to decrease during the second and third years of therapy. It is not known whether this reflects cumulative toxicity. In addition, the efficacy of other antiretroviral agents remains uncertain. Hence, adjunctive therapy for cognitive and motor symptoms of AIDS is important.
Patients will be randomized to one of the following 2 arms:
Arm 1 receives memantine plus concurrent antiretroviral therapy; Arm 2 receives placebo plus concurrent antiretroviral therapy. The initial dose of memantine is increased each week for the next 3 weeks, unless a maximum tolerated dose is reached. Following a 16-week evaluation period there is a 4-week washout prior to re-assessment. After the washout period, all patients, including those formerly randomized to the placebo arm, are given the opportunity to receive an open-label, 12-week administration of memantine. [AS PER AMENDMENT 4/6/99: The open-label phase is extended by 48 weeks to a total of 60 weeks of therapy. Patients who did not receive the initial 12 weeks of open-label treatment are eligible still for the 48-week open-label treatment phase.]
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 120 participants |
Intervention Model: | Parallel Assignment |
Primary Purpose: | Treatment |
Official Title: | A Phase II, Randomized, Double Blind, Placebo-Controlled Trial of Memantine for AIDS Dementia Complex (ADC) as Concurrent Treatment With Antiretroviral Therapy |
Study Start Date : | December 1996 |
Actual Study Completion Date : | July 2001 |

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
You may be eligible for this study if you:
- Are HIV positive.
- Have been diagnosed with AIDS dementia complex (ADC).
- Have an estimated IQ of at least 70 (before the onset of ADC) or the ability to read at a 6th grade level.
- Have impaired mental skills.
- Are age18 or older.
Exclusion Criteria
You will not be eligible for this study if you:
- Have a history of a neurologic disease unrelated to HIV infection.
- Have a history of chronic seizures or head injuries.
- Have a history of central nervous system infections.
- Have certain cancers.
- Have any psychiatric illness.
- Have an active AIDS-defining opportunistic infection.
- Are pregnant or breast-feeding.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000867
United States, California | |
UCLA CARE Center CRS | |
Los Angeles, California, United States, 90095 | |
Ucsf Aids Crs | |
San Francisco, California, United States, 94110 | |
United States, Florida | |
Univ. of Miami AIDS CRS | |
Miami, Florida, United States, 33136 | |
United States, Hawaii | |
Queens Med. Ctr. | |
Honolulu, Hawaii, United States, 96816 | |
Univ. of Hawaii at Manoa, Leahi Hosp. | |
Honolulu, Hawaii, United States, 96816 | |
United States, Illinois | |
Northwestern University CRS | |
Chicago, Illinois, United States, 60611 | |
Cook County Hosp. CORE Ctr. | |
Chicago, Illinois, United States, 60612 | |
United States, Kentucky | |
The Univ. of Kentucky, Lexington A2405 CRS | |
Lexington, Kentucky, United States, 40536-0226 | |
United States, Massachusetts | |
Bmc Actg Crs | |
Boston, Massachusetts, United States, 02118 | |
Beth Israel Deaconess - East Campus A0102 CRS | |
Boston, Massachusetts, United States, 02215 | |
United States, Missouri | |
Washington U CRS | |
St. Louis, Missouri, United States, 63110 | |
United States, Nebraska | |
Univ. of Nebraska Med. Ctr., Durham Outpatient Ctr. | |
Omaha, Nebraska, United States, 68198 | |
United States, New York | |
SUNY - Buffalo, Erie County Medical Ctr. | |
Buffalo, New York, United States, 14215 | |
Beth Israel Med. Ctr. (Mt. Sinai) | |
New York, New York, United States, 10003 | |
Mt. Sinai Med. Ctr. (N.Y.) A1801 CRS | |
New York, New York, United States, 10029 | |
Mt. Sinai Med. Ctr. A0404 CRS | |
New York, New York, United States, 10029 | |
Univ. of Rochester ACTG CRS | |
Rochester, New York, United States, 14642 | |
United States, Pennsylvania | |
Hosp. of the Univ. of Pennsylvania CRS | |
Philadelphia, Pennsylvania, United States, 19104 | |
United States, Washington | |
University of Washington AIDS CRS | |
Seattle, Washington, United States, 98104 |
Study Chair: | Bradford Navia | ||
Study Chair: | Richard Price |
Publications of Results:
Other Publications:
Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
ClinicalTrials.gov Identifier: | NCT00000867 History of Changes |
Other Study ID Numbers: |
ACTG 301 DAIDS-ES ID 10687 |
First Posted: | August 31, 2001 Key Record Dates |
Last Update Posted: | June 10, 2013 |
Last Verified: | June 2013 |
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Drug Therapy, Combination Administration, Oral AIDS Dementia Complex |
Zidovudine Anti-HIV Agents Memantine |
Additional relevant MeSH terms:
HIV Infections Dementia AIDS Dementia Complex Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Neurocognitive Disorders Mental Disorders Memantine Antiparkinson Agents Anti-Dyskinesia Agents Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Excitatory Amino Acid Antagonists Excitatory Amino Acid Agents |